US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bioxytran, Inc.

0.0500

+0.00142.88%

Volume:77.12K

Turnover:3.85K

Market Cap:4.96M

PE:-2.09

High:0.0500

Open:0.0486

Low:0.0486

Close:0.0486

52wk High:0.2283

52wk Low:0.0342

Shares:99.10M

Float Shares:98.60M

Volume Ratio:0.92

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0239

EPS(LYR):-0.0379

ROE:--

ROA:-687.83%

PB:-1.68

PE(LYR):-1.32

Loading ...

Overview Company News Filings

BRIEF-Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran

Bioxytran Reports 100% Viral Clearance in Phase 2 Trial of ProLectin-M

Bioxytran Inc - No Viral Rebounds Observed During 14-Day Post-Treatment Period

THOMSON REUTERS

Bioxytran CEO to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference

Bioxytran Inc. Partners with University of Minnesota to Advance Carbohydrate-Based Therapeutics

Bioxytran Reports Progress on Antiviral and Oxygen Transport Programs

Energy Fuels Announces $410 Million Rare Earth Processing Expansion in Utah

Bioxytran Inc. Terminates Officer Mike Sheikh

Energy Fuels Inc. Qualifies US-Produced Dysprosium Oxide for Permanent Magnet Use

Bioxytran Inc. Audit Chair Anders Utter Resigns

Bioxytran Inc. Director Alan M. Hoberman Reports Acquisition of Common Shares

BRIEF-Bioxytran Completes Randomized Clinical Trial For Its Broad-Spectrum Antiviral Drug

Titan Mining to produce graphite at New York facility, shares soar

Rare earth prices hit two-year peak after MP Materials stops China shipments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BIXT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIXT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIXT\",,,,,undefined,":{"symbol":"BIXT","market":"US","secType":"STK","nameCN":"Bioxytran, Inc.","latestPrice":0.05,"timestamp":1771441800000,"preClose":0.0486,"halted":0,"volume":77115,"delay":15,"changeRate":0.02880658436214003,"floatShares":98603900,"shares":99103900,"eps":-0.0239,"marketStatus":"Trading","change":0.0014,"latestTime":"02-18 14:10:00 EST Delay","open":0.0486,"high":0.05,"low":0.0486,"amount":3852.055960155,"amplitude":0.028807,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.0239,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.0486,"volumeRatio":0.91589},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIXT\",,,,,undefined,":{"symbol":"BIXT","floatShares":98603900,"roa":"-687.83%","roe":"--","lyrEps":-0.037945,"volumeRatio":0.91589,"shares":99103900,"dividePrice":0,"high":0.05,"amplitude":0.028807,"preClose":0.0486,"low":0.0486,"week52Low":0.0342,"pbRate":"-1.68","week52High":0.2283,"institutionHeld":0,"latestPrice":0.05,"eps":-0.0239,"divideRate":0,"volume":77115,"delay":15,"ttmEps":-0.0239,"open":0.0486,"prevYearClose":0.0758,"prevWeekClose":0.0486,"prevMonthClose":0.0426,"prevQuarterClose":0.0758,"fiveDayClose":0.0471,"twentyDayClose":0.0596,"sixtyDayClose":0.088},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIXT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIXT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIXT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIXT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610093691","title":"BRIEF-Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran","url":"https://stock-news.laohu8.com/highlight/detail?id=2610093691","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610093691?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:01","pubTimestamp":1770807712,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-MbioxytranFeb 11 (Reuters) - Bioxytran Inc BIXT.PK:BIOXYTRAN REPORTS POSITIVE PHASE 2 RESULTS DEMONS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUABBQPQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2610917936","title":"Bioxytran Reports 100% Viral Clearance in Phase 2 Trial of ProLectin-M","url":"https://stock-news.laohu8.com/highlight/detail?id=2610917936","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610917936?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807642,"startTime":"0","endTime":"0","summary":"Bioxytran Inc. announced positive results from a recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial of ProLectin-M in subjects with laboratory-confirmed acute viral infection. The study enrolled 38 subjects and evaluated orally administered ProLectin-M over a seven-day treatment period. According to the company, the trial demonstrated complete elimination of viral load in 100% of treated subjects by Day 7 compared to placebo , with a significant proportion achieving viral non-detection by Day 3. The results were presented by Bioxytran Inc., and the company plans to advance regulatory discussions and pursue late-stage clinical development of ProLectin-M for additional viral indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc6LqR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BIXT","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2610936931","title":"Bioxytran Inc - No Viral Rebounds Observed During 14-Day Post-Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936931?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUABBQPQN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2609535315","title":"Bioxytran CEO to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2609535315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609535315?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:26","pubTimestamp":1770240360,"startTime":"0","endTime":"0","summary":"Bioxytran Inc., a clinical-stage biotechnology company, will participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, February 5, 2026. CEO David Platt, Ph.D., is scheduled to present an overview of the company's corporate strategy and pipeline, followed by a fireside-style Q&A session with the virtual audience. A video webcast of the presentation will be available on Bioxytran's website and Channelchek.com for 90 days after the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL361pXM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2608865061","title":"Bioxytran Inc. Partners with University of Minnesota to Advance Carbohydrate-Based Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2608865061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608865061?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:01","pubTimestamp":1770033712,"startTime":"0","endTime":"0","summary":"Bioxytran Inc., a clinical-stage biotechnology company, has entered into a sponsored research collaboration with the University of Minnesota to advance the development of novel carbohydrate-based therapeutics. The partnership will focus on improving the understanding of polysaccharide and oligosaccharide interactions with biologically relevant targets. Under the agreement, research will be conducted at the University of Minnesota under the leadership of Dr. Kevin Mayo, an expert in biomolecular structure and nuclear magnetic resonance spectroscopy. Bioxytran will fund the project, which is expected to run through early 2027, while retaining broad rights to use the resulting research data for internal research and development. The University of Minnesota will maintain ownership of any intellectual property generated during the collaboration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL8TNjY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","BIXT","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4139","BK4112"],"gpt_icon":0},{"id":"2607053811","title":"Bioxytran Reports Progress on Antiviral and Oxygen Transport Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2607053811","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607053811?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:24","pubTimestamp":1769714654,"startTime":"0","endTime":"0","summary":"Bioxytran Inc. announced a corporate update highlighting progress across its multi-platform pipeline. The company reiterated its focus on advancing ProLectin-M, its lead antiviral program, which is being developed under an active U.S. FDA Investigational New Drug  framework. In October 2025, Bioxytran completed a randomized, double-blind, placebo-controlled clinical trial for ProLectin-M, with trial data expected to inform Phase 3 design and regulatory submissions. Dose optimization work for ProLectin-M was completed in May 2025 to support further clinical planning and agency interactions. Bioxytran also reported continued development of its oxygen-transport platform, including a universal oxygen carrier  and the use of the FDA-approved MDX Viewer device for tissue oxygenation measurement. In July 2024, Bioxytran announced a joint venture with the Heme Foundation to develop the UOC as an alternative to blood transfusions. Additionally, in January 2025, the company released a cancer-foc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL9DNB4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2603601836","title":"Energy Fuels Announces $410 Million Rare Earth Processing Expansion in Utah","url":"https://stock-news.laohu8.com/highlight/detail?id=2603601836","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603601836?lang=en_us&edition=fundamental","pubTime":"2026-01-15 19:15","pubTimestamp":1768475732,"startTime":"0","endTime":"0","summary":"Energy Fuels Inc. has announced a major expansion of its rare earth element processing capabilities at its White Mesa Mill in Utah, backed by a new Bankable Feasibility Study. The company plans to invest $410 million in a Phase 2 circuit expansion that will enable annual production of 6,000 tonnes of neodymium-praseodymium , 240 tonnes of dysprosium, and 66 tonnes of terbium. With this expansion, Energy Fuels aims to supply 45% of total U.S. rare earth demand in the near term, including 100% of domestic requirements for critical heavy rare earths by 2030. The project is expected to generate approximately $765 million in annual EBITDA over the first 15 years, positioning Energy Fuels as a leading, low-cost rare earth producer outside of China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"299b7b5e2278d20ee59743996ec46ee2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3GhtQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BIXT","UUUU","BK4606","BK4139"],"gpt_icon":1},{"id":"2601302668","title":"Bioxytran Inc. Terminates Officer Mike Sheikh","url":"https://stock-news.laohu8.com/highlight/detail?id=2601302668","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601302668?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:02","pubTimestamp":1767650537,"startTime":"0","endTime":"0","summary":"Bioxytran Inc. announced that Mike Sheikh was terminated as an officer of the company effective December 29, 2025. Sheikh is contesting the reason for his dismissal in a letter dated December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL9Qj5Bt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2592166842","title":"Energy Fuels Inc. Qualifies US-Produced Dysprosium Oxide for Permanent Magnet Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166842","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166842?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:15","pubTimestamp":1766142921,"startTime":"0","endTime":"0","summary":"Energy Fuels Inc. has announced a significant advancement in the U.S. rare earth supply chain with the successful production and qualification of high-purity dysprosium oxide at its White Mesa Mill in Utah. The company's dysprosium oxide, which achieved 99.9% purity, has passed initial quality assurance tests by a major South Korean automotive manufacturer for use in permanent magnets. Energy Fuels is the first U.S. company to have both \"light\" and \"heavy\" rare earth elements qualified for use in permanent magnet applications, a key milestone for national defense and industrial supply chains. The company plans to expand production to include terbium and potentially samarium oxides, with commercial-scale output of heavy rare earths expected as soon as the fourth quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL6JC88R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139","BK4606","BK4156","UUUU"],"gpt_icon":0},{"id":"2591648750","title":"Bioxytran Inc. Audit Chair Anders Utter Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648750","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648750?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:16","pubTimestamp":1765797377,"startTime":"0","endTime":"0","summary":"Bioxytran Inc. announced that Anders Utter has resigned from its Board of Directors and as Chair of the Audit Committee, effective immediately. The company has engaged an independent third-party financial expert to review its oversight, internal control, and approval processes following recommendations made by Utter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3bdfmz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0},{"id":"2584965201","title":"Bioxytran Inc. Director Alan M. Hoberman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965201","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965201?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:15","pubTimestamp":1763500543,"startTime":"0","endTime":"0","summary":"Alan M. Hoberman, Director of Bioxytran Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL3lDtqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bioxytran Inc. Director Alan M. Hoberman Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2579907730","title":"BRIEF-Bioxytran Completes Randomized Clinical Trial For Its Broad-Spectrum Antiviral Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2579907730","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579907730?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:37","pubTimestamp":1761748624,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxytran Completes Randomized Clinical Trial For Its Broad-Spectrum Antiviral DrugBioxytran Inc BIXT.PK:BIOXYTRAN COMPLETES RANDOMIZED CLINICAL TRIAL FOR ITS BROAD-SPECTRUM ANTIVIRAL DRUGSource text: ID:nGNX7bHyq8Further company coverage: BIXT.PK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA7WDJMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2575248464","title":"Titan Mining to produce graphite at New York facility, shares soar","url":"https://stock-news.laohu8.com/highlight/detail?id=2575248464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575248464?lang=en_us&edition=fundamental","pubTime":"2025-10-15 00:43","pubTimestamp":1760460232,"startTime":"0","endTime":"0","summary":"UPDATE 1-Titan Mining to produce graphite at New York facility, shares soarAdds shares and background in paragraph 2, 5 and 7By Katha  Kalia. Titan Mining TI.TO said on Tuesday it will begin production of graphite concentrate at its Empire State Mines in New York, days after China expanded export limits on rare earth minerals, sending its shares soaring 26.8% in afternoon trade.Titan plans to ramp up output to 40,000 tonnes per year, which it said could supply about half of the current U.S. natural graphite demand.\"China's decision to tighten graphite exports underscores the importance of a secure domestic supply,\" CEO Rita Adiani said, adding that the shift away from China would benefit Titan.Graphite, along with lithium, cobalt, aluminum, and rare earth elements such as neodymium and dysprosium, is critical for electric vehicle batteries, wind turbines and power grids.China dominates the global graphite market, refining more than 90% of the material.Beijing, which already restricted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nL3N3VV1EQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"2562735167","title":"Rare earth prices hit two-year peak after MP Materials stops China shipments","url":"https://stock-news.laohu8.com/highlight/detail?id=2562735167","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562735167?lang=en_us&edition=fundamental","pubTime":"2025-08-26 20:05","pubTimestamp":1756209937,"startTime":"0","endTime":"0","summary":"Rare earth prices hit two-year peak after MP Materials stops China shipmentsBy Eric Onstad and Amy Lv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nL8N3UD0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK4168","BK4588","600392","BIXT","BK0182","BK4585","MP","BK0084","BK0233","BK4139","IE00BD6J9T35.USD","LU0505663152.USD","BK0188"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}